All sponsors

Eisai Inc. $4523.T

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-33
RECRUITING2
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO71%

Delay Index: of 7 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +33.8 months). See all sponsors →

Open Eisai Inc. on the live radar map → 📅 $4523.T readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
CLEAR
NCT02811861
P3Active, not recruitingRenal Cell Carcinoma10692020-08-28 (-2 mo)
E2814
NCT06602258
P2Active, not recruitingAlzheimer's Disease1052026-12-03 (+6 mo)
Clarity AD
NCT03887455
P3Active, not recruitingEarly Alzheimer's Disease19062026-12-31 (+34 mo)
E2086
NCT07493265
P2RecruitingNarcolepsy642027-02-14
E7386
NCT04008797
P1/2Active, not recruitingEndometrial Neoplasms; Neoplasms3012027-03-31 (+72 mo)
Perampanel Oral Suspension
NCT04015141
P2Active, not recruitingPediatric Epileptic Syndrome; Partial-onset Seizures1002027-04-06 (+66 mo)
Lecanemab
NCT04468659
P3Active, not recruitingPreclinical Alzheimer's Disease; Early Preclinical Alzheimer's Disease14002028-12-21 (+14 mo)
Farletuzumab ecteribulin
NCT04300556
P1/2RecruitingSolid Tumor1822030-08-08 (+93 mo)